Author details

Full Name

Derek T O'Hagan

Affiliation

ORCID

Career Start Year

1988

Papers

212

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37163615	Broadly neutralizing antibodies against sarbecoviruses generated by immunization of macaques with an AS03-adjuvanted COVID-19 vaccine.	Sci Transl Med	2023
36711543	Extremely potent pan-sarbecovirus neutralizing antibodies generated by immunization of macaques with an AS03-adjuvanted monovalent subunit vaccine against SARS-CoV-2.	bioRxiv	2023
36564274	Systems analysis of human responses to an aluminium hydroxide-adsorbed TLR7 agonist (AS37) adjuvanted vaccine reveals a dose-dependent and specific activation of the interferon-mediated antiviral response.		2023
36680000	Maturation of Aluminium Adsorbed Antigens Contributes to the Creation of Homogeneous Vaccine Formulations.		2023
36732535	Author Correction: "World in motion" - emulsion adjuvants rising to meet the pandemic challenges.		2023
36678865	A Self-Emulsified Adjuvant System Containing the Immune Potentiator Alpha Tocopherol Induces Higher Neutralizing Antibody Responses than a Squalene-Only Emulsion When Evaluated with a Recombinant Cytomegalovirus (CMV) Pentamer Antigen in Mice.		2023
37514070	Aluminum Adjuvants-'Back to the Future'.		2023
34896446	The role of nanoparticle format and route of administration on self-amplifying mRNA vaccine potency.	Journal of Controlled Release	2022
35606518	Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in mice.	NPJ Vaccines	2022
35976993	Durable protection against the SARS-CoV-2 Omicron variant is induced by an adjuvanted subunit vaccine.	Sci Transl Med	2022
36713458	MRI/PET multimodal imaging of the innate immune response in skeletal muscle and draining lymph node post vaccination in rats.		2022
34934069	World in motion - emulsion adjuvants rising to meet the pandemic challenges.	npj Vaccines	2021
33572332	Conjugation of Mannans to Enhance the Potency of Liposome Nanoparticles for the Delivery of RNA Vaccines.	Pharmaceutics	2021
34264684	Lipid-Based Nanoparticles for Delivery of Vaccine Adjuvants and Antigens: Toward Multicomponent Vaccines.	Molecular Pharmaceutics	2021
33873199	Adjuvanting a subunit COVID-19 vaccine to induce protective immunity.	Nature	2021
33824489	Emerging concepts in the science of vaccine adjuvants.	Nat Rev Drug Discov	2021
33594366	Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates.	bioRxiv	2021
33152394	Rational design of adjuvants for subunit vaccines: The format of cationic adjuvants affects the induction of antigen-specific antibody responses.	Journal of Controlled Release	2021
34619077	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines.	Cell	2021
32619745	Delivery of self-amplifying mRNA vaccines by cationic lipid nanoparticles: The impact of cationic lipid selection.	Journal of Controlled Release	2020
32247804	Design of a novel vaccine nanotechnology-based delivery system comprising CpGODN-protein conjugate anchored to liposomes.	Journal of Controlled Release	2020
32063436	Adsorption onto aluminum hydroxide adjuvant protects antigens from degradation.	Vaccine	2020
32397231	Investigating the Impact of Delivery System Design on the Efficacy of Self-Amplifying RNA Vaccines.	Vaccines	2020
32551244	Synthesis of protein conjugates adsorbed on cationic liposomes surface.	MethodsX	2020
33257234	The continued advance of vaccine adjuvants - 'we can work it out'.	Seminars in Immunology	2020
32821824	Development of a potent Zika virus vaccine using self-amplifying messenger RNA.	Science advances	2020
33024579	Technological approaches to streamline vaccination schedules, progressing towards single-dose vaccines.	npj Vaccines	2020
31395915	The droplet size of emulsion adjuvants has significant impact on their potency, due to differences in immune cell-recruitment and -activation.	Scientific Reports	2019
31678654	Formulation Design, Optimization and In Vivo Evaluations of an Î±-Tocopherol-Containing Self-Emulsified Adjuvant System using Inactivated Influenza Vaccine.	Journal of Controlled Release	2019
31669193	Adjuvant effect of TLR7 agonist adsorbed on aluminum hydroxide (AS37): A phase I randomized, dose escalation study of an AS37-adjuvanted meningococcal C conjugated vaccine.	Clinical Immunology	2019
31290323	Mannosylation of LNP Results in Improved Potency for Self-Amplifying RNA (SAM) Vaccines.	ACS Infectious Diseases	2019
29421216	The Preparation and Physicochemical Characterization of Aluminum Hydroxide/TLR7a, a Novel Vaccine Adjuvant Comprising a Small Molecule Adsorbed to Aluminum Hydroxide.	Journal of Pharmaceutical Sciences	2018
29883663	Stable Nanoemulsions for the Delivery of Small Molecule Immune Potentiators.	Journal of Pharmaceutical Sciences	2018
30323958	Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want.	npj Vaccines	2018
29296883	Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs.	Blood Adv	2017
28645718	Optimizing adjuvants for intradermal delivery of MenC glycoconjugate vaccine.	Vaccine	2017
28823618	Addition of a TLR7 agonist to an acellular pertussis vaccine enhances Th1 and Th17 responses and protective immunity in a mouse model.	Vaccine	2017
28592561	Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake.	Science Translational Medicine	2017
28755542	Towards an evidence based approach for the development of adjuvanted vaccines.		2017
28701102	Mechanism of action of mRNA-based vaccines.	Expert Review of Vaccines	2017
27270029	Incorporation of Phosphonate into Benzonaphthyridine Toll-like Receptor 7 Agonists for Adsorption to Aluminum Hydroxide.	Journal of Medicinal Chemistry	2016
27439378	Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines.	Scientific Reports	2016
27388628	The adjuvant effect of TLR7 agonist conjugated to a meningococcal serogroup C glycoconjugate vaccine.	European Journal of Pharmaceutics and Biopharmaceutics	2016
27224856	The preparation and characterization of PLG nanoparticles with an entrapped synthetic TLR7 agonist and their preclinical evaluation as adjuvant for an adsorbed DTaP vaccine.	European Journal of Pharmaceutics and Biopharmaceutics	2016
26784684	Multiplex immunoassay for in vitro characterization of acellular pertussis antigens in combination vaccines.	Vaccine	2016
26022561	New generation adjuvants--from empiricism to rational design.	Vaccine	2015
25930118	Fabrication of cell culture-derived influenza vaccine dissolvable microstructures and evaluation of immunogenicity in guinea pigs.	Vaccine	2015
25867449	Rational Design of Adjuvant for Skin Delivery: Conjugation of Synthetic Î²-Glucan Dectin-1 Agonist to Protein Antigen.	Molecular Pharmaceutics	2015
25775551	Vaccine composition formulated with a novel TLR7-dependent adjuvant induces high and broad protection against Staphylococcus aureus.	Proceedings of the National Academy of Sciences of the United States of America	2015
25858157	Analysis of immunoglobulin transcripts and hypermutation following SHIV(AD8) infection and protein-plus-adjuvant immunization.	Nat Commun	2015